PWRM pursues an aggressive intellectual property strategy to protect its inventions and discoveries made on its own and with its collaborators. Power3 Medical works with key physician scientists at major medical research and treatment centers. With access to decisive human clinical samples and superior trade secret proteomic methodologies, the Company provides solutions to pressing challenges in diagnosis and treatment of patients and has concluded research agreements, technology license agreements, and filed provisional and utility patents. Power3 is also adding additional layers of research and license agreements, patent filings, and trade secrets, as its technology and product portfolio develops.
Power3 Medical Products, Inc., a leading proteomics company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases, announced today that it delivered four poster presentations at the 2010 International Conference on Alzheimer's Disease (ICAD) in Honolulu, Hawaii. These presentations discussed NuroPro®, Power3's diagnostic test, and focused on Power3's Alzheimer's disease blood serum biomarkers, test and clinical validation trials.
"In preparation for commercialization, our objective at this meeting was to show how Power3's protein biomarkers and blood tests provide superior solutions for diagnosis and drug response to improve the treatment of Alzheimer's disease," said Dr. Ira L. Goldknopf, Power3's President and Chief Scientific Officer. "It was gratifying to receive substantial attention to our posters from representatives of major pharma and clinical research institutions from around the world. They expressed surprise and enthusiasm for our findings, especially those relating to the methods by which Power3's protein biomarkers indicate how patients respond to treatment with the three major anti-dementia drugs."
"We are pleased that our blood tests specifically diagnose Alzheimer's in patients, both pre- and post-treatment,"
"We are within striking distance of realizing an Alzheimer's clinical diagnostic tool which I hope will lead to a greater understanding of the disease and buoy the pace of future therapeutic interventions,"
Power3 has filed several patent applications for its NuroPro® technology that are currently pending. Power3 also has a world-wide exclusive license from the Baylor College of Medicine in Houston, Texas. To date, Power3 has given 9 presentations on NuroPro at international scientific meetings in the United States, Europe and China, and has published 6 articles in peer-reviewed scientific journals on the subject. Power3 intends to publish these latest findings as well.
Health Management Associates Inc. (NYSE: HMA) announced its consolidated financial results for its third quarter and nine months ended September 30, 2010. For the quarter, Health Management reported net revenue of $1,270.7 million and earnings before interest, income taxes, depreciation and amortization, and certain other items of $171.2 million. During the third quarter, income from continuing operations was $39.9 million and net income attributable to Health Management’s common stockholders was $35.3 million, or $0.14 per diluted share, a 40.0% increase as compared to $0.10 for the same quarter a year ago. Health Management enables America's best local health care by providing the people, processes, capital and expertise necessary for its hospital and physician partners to fulfill their local missions of delivering superior health care services.
Radian Group Inc. (NYSE: RDN) announced that it will hold a conference call on Tuesday, November 2, 2010, at 10:00 a.m. Eastern time to discuss the company’s third quarter 2010 results, which will be announced prior to the market open on the same day. The company also reported that its mortgage insurance primary delinquency inventory declined by approximately 1 percent from August to September, and by approximately 6 percent from the second quarter to the third quarter of 2010. This includes the impact of terminations of certain structured transactions during the quarter, which reduced the delinquency count by approximately 3 percent. Radian Group Inc. (NYSE:RDN), headquartered in Philadelphia, provides private mortgage insurance and related risk mitigation products and services to mortgage lenders nationwide through its principal operating subsidiary, Radian Guaranty Inc.
NV Energy, Inc. (NYSE: NVE) says it is eyeing a potential rate increase of just less than 5 percent for Southern Nevada customers. In a filing, the utility says it will need an April 1 rate hike to recoup expenses and revenue involving power conservation efforts.
A 2009 state law requires NV Energy to change the way it accounts for the financial effects of the energy-efficiency programs. NV Energy says the programs are more cost-effective than building new generation sources.
NV Energy, Inc., through its subsidiaries, engages in the generation, transmission, and distribution of electric energy in southern Nevada. It operates in three segments: NPC Electric, SPPC Electric, and SPPC Natural Gas.
Sign-Up For Free Stock Alerts At http://crwepicks.com/
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.The CRWEPicks.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer ( http://crwepicks.com/
# # #
Crown Equity Holdings Inc. assists and consults with domestic and foreign companies interested in becoming publicly traded in the U.S. The company designs and manufactures multi-monitor computer systems for financial traders and audio/video professionals.